Sponsor or institution

Clinical trials and research at Exelixis

• 8Clinical trials
• 21Countries

Newest trials

All recruiting trials (8)

• Zanzalintinib alone or with Pembrolizumab and Berahyaluronidase Alfa in colorectal cancer with molecular residual disease

  This trial tests whether zanzalintinib alone or with pembrolizumab and berahyaluronidase alfa can help people with stage II/III colorectal cancer who still have MRD detected by a Signatera test after surgery.

  Recruiting at 13 sites Phase 3 Exelixis · Council Bluffs, Iowa and 12 other locations · NCT07750158

• Zanzalintinib for recurrent or progressive meningioma

  This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.

  Recruiting at 20 sites Phase 2 Exelixis · Birmingham, Alabama and 19 other locations · NCT07428616

• XB371 for people with locally advanced or metastatic solid tumors

  This trial will test whether XB371 is safe and tolerable in people with locally advanced or metastatic solid tumors.

  Recruiting at 9 sites Phase 1 Exelixis · Rogers, Arkansas and 8 other locations · NCT07123103

• Single-dose zanzalintinib testing in people with moderate liver impairment

  This will test how one dose of zanzalintinib behaves in the blood of people with moderate liver impairment compared with healthy people.

  Recruiting at 2 sites Phase 1 Exelixis · Orlando, Florida and 1 other locations · NCT06962332

• Testing XB628 for advanced or metastatic solid tumors

  This study is testing a new treatment called XB628 to see if it can help people with advanced or metastatic solid tumors by finding the right dose that is safe and effective.

  Recruiting at 11 sites Phase 1 Exelixis · San Francisco, California and 10 other locations · NCT06952010

• Zanzalintinib versus everolimus for advanced or metastatic pancreatic and extra‑pancreatic neuroendocrine tumors

  This trial tests whether zanzalintinib works better than everolimus for people with previously treated, unresectable or metastatic pancreatic or extra‑pancreatic neuroendocrine tumors.

  Recruiting at 134 sites Phase 2/3 Exelixis · Birmingham, Alabama and 134 other locations · NCT06943755

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

• Zanzalintinib with immune checkpoint drugs for advanced solid tumors

  This trial will test whether zanzalintinib alone or combined with immune drugs (nivolumab, with or without ipilimumab or relatlimab) is safe and helps people with advanced or metastatic solid tumors such as renal cell, prostate, urothelial, and liver cancers.

  Recruiting at 101 sites Phase 1 Exelixis · Phoenix, Arizona and 121 other locations · NCT05176483

Quick answers

How many clinical trials run by Exelixis are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (8 trials), United Kingdom (3 trials), Australia (2 trials), Austria (2 trials), Belgium (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 2: 1, Phase 3: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →